Advertisement

Response to comment on “Impact of DNA damage repair defects on response to radium-223 and overall survival in metastatic castration-resistant prostate cancer”

Published:December 25, 2020DOI:https://doi.org/10.1016/j.ejca.2020.11.041
      We thank colleagues De Vincentis and Frantellizzi [
      • De Vincentis G.
      • Frantellizzi V.
      Comment on: ‘Impact of DNA damage repair defects on response to radium-223 and overall survival in metastatic castration-resistant prostate cancer’ by De Vincentis et al..
      ] for their thoughtful considerations on our recently published manuscript in this journal and their ongoing work on optimising patient selection for radium-223 therapy [
      • De Vincentis G.
      • Frantellizzi V.
      Comment on: ‘Impact of DNA damage repair defects on response to radium-223 and overall survival in metastatic castration-resistant prostate cancer’ by De Vincentis et al..
      ,
      • van der Doelen M.J.
      • Isaacsson Velho P.
      • Slootbeek P.H.J.
      • Pamidimarri Naga S.
      • Bormann M.
      • van Helvert S.
      • et al.
      Impact of DNA damage repair defects on response to radium-223 and overall survival in metastatic castration-resistant prostate cancer.
      ].
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • De Vincentis G.
        • Frantellizzi V.
        Comment on: ‘Impact of DNA damage repair defects on response to radium-223 and overall survival in metastatic castration-resistant prostate cancer’ by De Vincentis et al..
        Eur J Cancer. 2020; ([in press])https://doi.org/10.1016/j.ejca.2020.09.041
        • van der Doelen M.J.
        • Isaacsson Velho P.
        • Slootbeek P.H.J.
        • Pamidimarri Naga S.
        • Bormann M.
        • van Helvert S.
        • et al.
        Impact of DNA damage repair defects on response to radium-223 and overall survival in metastatic castration-resistant prostate cancer.
        Eur J Cancer. 2020; 136: 16-24
        • de Bono J.
        • Mateo J.
        • Fizazi K.
        • Saad F.
        • Shore N.
        • Sandhu S.
        • et al.
        Olaparib for metastatic castration-resistant prostate cancer.
        N Engl J Med. 2020; 382: 2091-2102
        • Slootbeek P.H.J.
        • Duizer M.L.
        • van der Doelen M.J.
        • Kloots I.S.H.
        • Kuppen M.C.P.
        • Westgeest H.M.
        • et al.
        Impact of DNA damage repair defects and aggressive variant features on response to carboplatin-based chemotherapy in metastatic castration-resistant prostate cancer.
        Int J Cancer. 2021; 148: 385-395
        • Mateo J.
        • Cheng H.H.
        • Beltran H.
        • Dolling D.
        • Xu W.
        • Pritchard C.C.
        • et al.
        Clinical outcome of prostate cancer patients with germline DNA repair mutations: retrospective analysis from an international study.
        Eur Urol. 2018; 73: 687-693
        • Lozano Mejorada R.
        • Castro Marcos E.
        • Aragon I.M.
        • Thorne H.
        • Lopez Campos F.
        • Sanz A.
        • et al.
        612MO Clinical impact of somatic alterations in prostate cancer patients with and without previously known germline BRCA1/2 mutations: results from PROREPAIR-A study.
        Ann Oncol. 2020; 31: S509-S510
        • Castro E.
        • Mejorada R.L.
        • Saez M.
        • De Giorgi U.F.F.
        • Aragón I.
        • Laorden N.R.
        • et al.
        876P - Impact of germline mutations in homologous recombination (HR) genes on the response to Radium-223 for metastatic castration resistant prostate cancer (mCRPC)..
        Ann Oncol. 2019; 30: v343-v344
        • Van der Doelen M.J.
        • Mehra N.
        • Hermsen R.
        • Janssen M.J.R.
        • Gerritsen W.R.
        • Van Oort I.M.
        Patient selection for radium-223 therapy in patients with bone metastatic castration-resistant prostate cancer: new recommendations and future perspectives.
        Clin Genitourin Cancer. 2019; 17: 79-87
        • Frantellizzi V.
        • Farcomeni A.
        • Follacchio G.A.
        • Pacilio M.
        • Pellegrini R.
        • Pani R.
        • et al.
        A 3-variable prognostic score (3-PS) for overall survival prediction in metastatic castration-resistant prostate cancer treated with (223)Radium-dichloride.
        Ann Nucl Med. 2018; 32: 142-148
        • van Dessel L.F.
        • van Riet J.
        • Smits M.
        • Zhu Y.
        • Hamberg P.
        • van der Heijden M.S.
        • et al.
        The genomic landscape of metastatic castration-resistant prostate cancers reveals multiple distinct genotypes with potential clinical impact.
        Nat Commun. 2019; 10: 5251

      Linked Article